These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29425482)

  • 1. To Bind or Not to Bind: Unravelling GPCR Polypharmacology.
    Sexton PM; Christopoulos A
    Cell; 2018 Feb; 172(4):636-638. PubMed ID: 29425482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational studies to predict or explain G protein coupled receptor polypharmacology.
    Jacobson KA; Costanzi S; Paoletta S
    Trends Pharmacol Sci; 2014 Dec; 35(12):658-63. PubMed ID: 25458540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addressing selective polypharmacology of antipsychotic drugs targeting the bioaminergic receptors through receptor dynamic conformational ensembles.
    Selvam B; Porter SL; Tikhonova IG
    J Chem Inf Model; 2013 Jul; 53(7):1761-74. PubMed ID: 23789628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polypharmacology of dopamine receptor ligands.
    Butini S; Nikolic K; Kassel S; Brückmann H; Filipic S; Agbaba D; Gemma S; Brogi S; Brindisi M; Campiani G; Stark H
    Prog Neurobiol; 2016 Jul; 142():68-103. PubMed ID: 27234980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical Diversity in the G Protein-Coupled Receptor Superfamily.
    Vass M; Kooistra AJ; Yang D; Stevens RC; Wang MW; de Graaf C
    Trends Pharmacol Sci; 2018 May; 39(5):494-512. PubMed ID: 29576399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polypharmacology: in silico methods of ligand design and development.
    McKie SA
    Future Med Chem; 2016 Apr; 8(5):579-602. PubMed ID: 27105127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs.
    Lee SM; Booe JM; Pioszak AA
    Eur J Pharmacol; 2015 Sep; 763(Pt B):196-205. PubMed ID: 25981303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From biased signalling to polypharmacology: unlocking unique intracellular signalling using pepducins.
    Carr R; Benovic JL
    Biochem Soc Trans; 2016 Apr; 44(2):555-61. PubMed ID: 27068969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polypharmacology: The science of multi-targeting molecules.
    Kabir A; Muth A
    Pharmacol Res; 2022 Feb; 176():106055. PubMed ID: 34990865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GES polypharmacology fingerprints: a novel approach for drug repositioning.
    Pérez-Nueno VI; Karaboga AS; Souchet M; Ritchie DW
    J Chem Inf Model; 2014 Mar; 54(3):720-34. PubMed ID: 24494653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polypharmacology: challenges and opportunities in drug discovery.
    Anighoro A; Bajorath J; Rastelli G
    J Med Chem; 2014 Oct; 57(19):7874-87. PubMed ID: 24946140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoproteomic Approach to Explore the Target Profile of GPCR ligands: Application to 5-HT1A and 5-HT6 Receptors.
    Gamo AM; González-Vera JA; Rueda-Zubiaurre A; Alonso D; Vázquez-Villa H; Martín-Couce L; Palomares Ó; López JA; Martín-Fontecha M; Benhamú B; López-Rodríguez ML; Ortega-Gutiérrez S
    Chemistry; 2016 Jan; 22(4):1313-21. PubMed ID: 26560738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compartmentalization of GPCR signalling controls unique cellular responses.
    Ellisdon AM; Halls ML
    Biochem Soc Trans; 2016 Apr; 44(2):562-7. PubMed ID: 27068970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantifying the tendency of therapeutic target proteins to bind promiscuous or selective compounds.
    Hu Y; Bajorath J
    PLoS One; 2015; 10(5):e0126838. PubMed ID: 26000736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. X-ray structure breakthroughs in the GPCR transmembrane region.
    Topiol S; Sabio M
    Biochem Pharmacol; 2009 Jul; 78(1):11-20. PubMed ID: 19447219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts.
    Ma X; Lv X; Zhang J
    Eur J Med Chem; 2018 Jan; 143():449-463. PubMed ID: 29202407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural mechanism of GPCR-arrestin interaction: recent breakthroughs.
    Park JY; Lee SY; Kim HR; Seo MD; Chung KY
    Arch Pharm Res; 2016 Mar; 39(3):293-301. PubMed ID: 26825061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polypharmacology in Drug Development: A Minireview of Current Technologies.
    Tan Z; Chaudhai R; Zhang S
    ChemMedChem; 2016 Jun; 11(12):1211-8. PubMed ID: 27154144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the GPCR biased signaling through G protein and arrestin complex structures.
    Zhou XE; Melcher K; Xu HE
    Curr Opin Struct Biol; 2017 Aug; 45():150-159. PubMed ID: 28558341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingolipids in the function of G protein-coupled receptors.
    Jafurulla M; Chattopadhyay A
    Eur J Pharmacol; 2015 Sep; 763(Pt B):241-6. PubMed ID: 26164794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.